Modified bacterial system for vivo direction evolution

Information

  • Research Project
  • 6791132
  • ApplicationId
    6791132
  • Core Project Number
    R43GM071252
  • Full Project Number
    1R43GM071252-01
  • Serial Number
    71252
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2004 - 20 years ago
  • Project End Date
    3/31/2006 - 18 years ago
  • Program Officer Name
    PORTNOY, MATTHEW
  • Budget Start Date
    4/1/2004 - 20 years ago
  • Budget End Date
    3/31/2006 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/29/2004 - 20 years ago

Modified bacterial system for vivo direction evolution

DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new genetic system that will mimic the natural process of evolution for a selected subset of genes inside of a bacterial cell. Instead of an evolutionary time scale of years, evolution will proceed at an accelerated rate and data will be collected in a matter of days. In addition to providing a powerful system to study evolution in the laboratory, such a system will form the core of a directed evolution technology. Directed evolution is an approach that enables scientists to "tune" the properties of enzymes for specific applications. Its benefit has become so apparent that today most new enzymes undergo some type of directed evolution before being commercialized. However, all current implementations of directed evolution are conducted step-wise, with each step in the evolution process necessitating a substantial amount of time and manpower. A single cycle of evolution usually takes a few days and involves demanding technical work at each step. Because enzymes usually need to undergo many cycles of evolution, each application can take a substantial amount of time. This proposal will yield a continuous in vivo directed evolution platform requiring only minimal external input. Such an evolution platform will enable scientists to conduct more than 20 cycles of evolution in the course of a single day. It thus has the potential to be 10X faster than current evolution technologies, 10X cheaper, easier to implement, and yield proteins that will theoretically be better optimized than those produced today. Such a system will enable the optimization of proteins for various industrial applications (catalysts for pharmaceutical chemical synthesis is one example), but more importantly, it will be adapted to mammalian systems to enable the in vivo evolution of peptide-based therapeutics (such as antibodies, cyclic peptides, and enzymes). These therapeutics will address critical areas such as antiviral and antimicrobial drugs.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    252798
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:252798\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    POTENTIA PHARMACEUTICALS, INC
  • Organization Department
  • Organization DUNS
    144375263
  • Organization City
    LOUISVILLE
  • Organization State
    KY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    40202
  • Organization District
    UNITED STATES